Cargando…

Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience

OBJECTIVE: The aim of this study is to evaluate the feasibility, safety, and short-term effectiveness of a high-power (150 W) microwave ablation (MWA) device for tumor ablation in the lung, liver, and kidney. METHODS: Between December 2021 and June 2022, patients underwent high-power MWA for liver,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lanza, Carolina, Carriero, Serena, Ascenti, Velio, Tintori, Jacopo, Ricapito, Francesco, Lavorato, Roberto, Biondetti, Pierpaolo, Angileri, Salvatore Alessio, Piacentino, Filippo, Fontana, Federico, Venturini, Massimo, Ierardi, Anna Maria, Carrafiello, Gianpaolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467382/
https://www.ncbi.nlm.nih.gov/pubmed/37608585
http://dx.doi.org/10.1177/15330338231185277
_version_ 1785099098972487680
author Lanza, Carolina
Carriero, Serena
Ascenti, Velio
Tintori, Jacopo
Ricapito, Francesco
Lavorato, Roberto
Biondetti, Pierpaolo
Angileri, Salvatore Alessio
Piacentino, Filippo
Fontana, Federico
Venturini, Massimo
Ierardi, Anna Maria
Carrafiello, Gianpaolo
author_facet Lanza, Carolina
Carriero, Serena
Ascenti, Velio
Tintori, Jacopo
Ricapito, Francesco
Lavorato, Roberto
Biondetti, Pierpaolo
Angileri, Salvatore Alessio
Piacentino, Filippo
Fontana, Federico
Venturini, Massimo
Ierardi, Anna Maria
Carrafiello, Gianpaolo
author_sort Lanza, Carolina
collection PubMed
description OBJECTIVE: The aim of this study is to evaluate the feasibility, safety, and short-term effectiveness of a high-power (150 W) microwave ablation (MWA) device for tumor ablation in the lung, liver, and kidney. METHODS: Between December 2021 and June 2022, patients underwent high-power MWA for liver, lung, and kidney tumors. A retrospective observational study was conducted in accordance with the Declaration of Helsinki. The MWA system utilized a 150-W, 2.45-GHz microwave generator (Emprint™ HP Ablation System, Medtronic). The study assessed technical success, safety, and effectiveness, considering pre- and post-treatment diameter and volume, lesion location, biopsy and/or cone beam computed tomography (CBCT) usage, MWA ablation time, MWA power, and dose-area product (DAP). RESULTS: From December 2021 to June 2022, 16 patients were enrolled for high-power MWA. Treated lesions included hepatocellular carcinoma (10), liver metastasis from colon cancer (1), liver metastasis from pancreatic cancer (1), squamous cell lung carcinoma (2), renal cell carcinoma (1), and renal oncocytoma (1). Technical success rate was 100%. One grade 1 complication (6.25%) was reported according to CIRSE classification. Overall effectiveness was 92.8%. Pre- and post-treatment mean diameters for liver lesions were 19.9 mm and 37.5 mm, respectively; for kidney lesions, 34 mm and 35 mm; for lung lesions, 29.5 mm and 31.5 mm. Pre- and post-treatment mean volumes for liver lesions were 3.4 ml and 24 ml, respectively; for kidney lesions, 8.2 ml and 20.5 ml; for lung lesions, 10.2 ml and 32.7 ml. The mean ablation time was 48 minutes for liver, 42.5 minutes for lung, and 42.5 minutes for renal ablation. The mean DAP for all procedures was 40.83 Gcm(2). CONCLUSION: This preliminary study demonstrates the feasibility, safety, and effectiveness of the new 150 W MWA device. Additionally, it shows reduced ablation times for large lesions.
format Online
Article
Text
id pubmed-10467382
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-104673822023-08-31 Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience Lanza, Carolina Carriero, Serena Ascenti, Velio Tintori, Jacopo Ricapito, Francesco Lavorato, Roberto Biondetti, Pierpaolo Angileri, Salvatore Alessio Piacentino, Filippo Fontana, Federico Venturini, Massimo Ierardi, Anna Maria Carrafiello, Gianpaolo Technol Cancer Res Treat New tools in loco-regional treatments: state of art and future directions OBJECTIVE: The aim of this study is to evaluate the feasibility, safety, and short-term effectiveness of a high-power (150 W) microwave ablation (MWA) device for tumor ablation in the lung, liver, and kidney. METHODS: Between December 2021 and June 2022, patients underwent high-power MWA for liver, lung, and kidney tumors. A retrospective observational study was conducted in accordance with the Declaration of Helsinki. The MWA system utilized a 150-W, 2.45-GHz microwave generator (Emprint™ HP Ablation System, Medtronic). The study assessed technical success, safety, and effectiveness, considering pre- and post-treatment diameter and volume, lesion location, biopsy and/or cone beam computed tomography (CBCT) usage, MWA ablation time, MWA power, and dose-area product (DAP). RESULTS: From December 2021 to June 2022, 16 patients were enrolled for high-power MWA. Treated lesions included hepatocellular carcinoma (10), liver metastasis from colon cancer (1), liver metastasis from pancreatic cancer (1), squamous cell lung carcinoma (2), renal cell carcinoma (1), and renal oncocytoma (1). Technical success rate was 100%. One grade 1 complication (6.25%) was reported according to CIRSE classification. Overall effectiveness was 92.8%. Pre- and post-treatment mean diameters for liver lesions were 19.9 mm and 37.5 mm, respectively; for kidney lesions, 34 mm and 35 mm; for lung lesions, 29.5 mm and 31.5 mm. Pre- and post-treatment mean volumes for liver lesions were 3.4 ml and 24 ml, respectively; for kidney lesions, 8.2 ml and 20.5 ml; for lung lesions, 10.2 ml and 32.7 ml. The mean ablation time was 48 minutes for liver, 42.5 minutes for lung, and 42.5 minutes for renal ablation. The mean DAP for all procedures was 40.83 Gcm(2). CONCLUSION: This preliminary study demonstrates the feasibility, safety, and effectiveness of the new 150 W MWA device. Additionally, it shows reduced ablation times for large lesions. SAGE Publications 2023-08-22 /pmc/articles/PMC10467382/ /pubmed/37608585 http://dx.doi.org/10.1177/15330338231185277 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).
spellingShingle New tools in loco-regional treatments: state of art and future directions
Lanza, Carolina
Carriero, Serena
Ascenti, Velio
Tintori, Jacopo
Ricapito, Francesco
Lavorato, Roberto
Biondetti, Pierpaolo
Angileri, Salvatore Alessio
Piacentino, Filippo
Fontana, Federico
Venturini, Massimo
Ierardi, Anna Maria
Carrafiello, Gianpaolo
Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience
title Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience
title_full Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience
title_fullStr Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience
title_full_unstemmed Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience
title_short Percutaneous Application of High Power Microwave Ablation With 150 W for the Treatment of Tumors in Lung, Liver, and Kidney: A Preliminary Experience
title_sort percutaneous application of high power microwave ablation with 150 w for the treatment of tumors in lung, liver, and kidney: a preliminary experience
topic New tools in loco-regional treatments: state of art and future directions
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10467382/
https://www.ncbi.nlm.nih.gov/pubmed/37608585
http://dx.doi.org/10.1177/15330338231185277
work_keys_str_mv AT lanzacarolina percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT carrieroserena percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT ascentivelio percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT tintorijacopo percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT ricapitofrancesco percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT lavoratoroberto percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT biondettipierpaolo percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT angilerisalvatorealessio percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT piacentinofilippo percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT fontanafederico percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT venturinimassimo percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT ierardiannamaria percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience
AT carrafiellogianpaolo percutaneousapplicationofhighpowermicrowaveablationwith150wforthetreatmentoftumorsinlungliverandkidneyapreliminaryexperience